Literature DB >> 23913154

Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography.

Jun Ouyang1.   

Abstract

Hydrophobic interaction chromatography (HIC) is the method of choice for determination of the drug-to-antibody ratio (DAR) and drug load distribution for cysteine (Cys)-linked antibody-drug conjugates (ADCs). The drug-loaded species are resolved based on the increasing hydrophobicity with the least hydrophobic, unconjugated form eluting first and the most hydrophobic, 8-drug form eluting last. The area percentage of a peak represents the relative distribution of the particular drug-loaded ADC species. The weighted average DAR is then calculated using the percentage peak area information and the drug load numbers. Reversed phase high-performance liquid chromatography (RP-HPLC) offers an orthogonal method to obtain DAR for Cys-linked ADCs. The method involves, first, a reduction reaction to completely dissociate the heavy and light chains of the ADC, then separation of the light and heavy chains and their corresponding drug-loaded forms on an RP column. The percentage peak area from integration of the light chain and heavy chain peaks, combined with the assigned drug load for each peak, is used to calculate the weighted average DAR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913154     DOI: 10.1007/978-1-62703-541-5_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

1.  Quantitative collision-induced unfolding differentiates model antibody-drug conjugates.

Authors:  Yuwei Tian; Jennifer L Lippens; Chawita Netirojjanakul; Iain D G Campuzano; Brandon T Ruotolo
Journal:  Protein Sci       Date:  2018-12-22       Impact factor: 6.725

Review 2.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

3.  Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.

Authors:  Zhaoxiong Ma; Hua He; Fumou Sun; Yao Xu; Xuequn Huang; Yuexing Ma; Hong Zhao; Yang Wang; Min Wang; Juan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-23       Impact factor: 4.553

4.  Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.

Authors:  Julien Marcoux; Thierry Champion; Olivier Colas; Elsa Wagner-Rousset; Nathalie Corvaïa; Alain Van Dorsselaer; Alain Beck; Sarah Cianférani
Journal:  Protein Sci       Date:  2015-03-31       Impact factor: 6.725

5.  Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Authors:  L Nathan Tumey; Carolyn A Leverett; Beth Vetelino; Fengping Li; Brian Rago; Xiaogang Han; Frank Loganzo; Sylvia Musto; Guoyun Bai; Sai Chetan K Sukuru; Edmund I Graziani; Sujiet Puthenveetil; Jeffrey Casavant; Anokha Ratnayake; Kimberly Marquette; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Lioudmila Tchistiakova; Andrew J Bessire; Tracey Clark; Judy Lucas; Christine Hosselet; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-06-22       Impact factor: 4.345

6.  Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control.

Authors:  Yubo Tang; Feng Tang; Yang Yang; Lei Zhao; Hu Zhou; Jinhua Dong; Wei Huang
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

7.  Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.

Authors:  Calvin D Lewis; Abhay K Singh; Fong-Fu Hsu; Dinesh Thotala; Dennis E Hallahan; Vaishali Kapoor
Journal:  Clin Cancer Res       Date:  2021-06-01       Impact factor: 13.801

8.  Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.

Authors:  Fumou Sun; Tong Wang; Jiahao Jiang; Yang Wang; Zhaoxiong Ma; Zhaoting Li; Yue Han; Mingzhu Pan; Jialing Cai; Min Wang; Juan Zhang
Journal:  Oncotarget       Date:  2017-04-19

Review 9.  Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.

Authors:  Nirnoy Dan; Saini Setua; Vivek K Kashyap; Sheema Khan; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-09

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.